Tomoshige K, Stuart W, Fink Baldauf I, Ito M, Tsuchiya T, Nagayasu T, et al. FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung. Cancer Res. 2023;83:1443-1458 pubmed publisher

Liu H, Gong Z, Li K, Zhang Q, Xu Z, Xu Y. SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma. J Exp Clin Cancer Res. 2021;40:75 pubmed publisher

Pelullo M, Nardozza F, Zema S, Quaranta R, Nicoletti C, Besharat Z, et al. Kras/ADAM17-Dependent Jag1-ICD Reverse Signaling Sustains Colorectal Cancer Progression and Chemoresistance. Cancer Res. 2019;79:5575-5586 pubmed publisher

Li S, Liu S, Deng J, Akbay E, Hai J, Ambrogio C, et al. Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clin Cancer Res. 2018;24:4854-4864 pubmed publisher

Ganier O, Schnerch D, Oertle P, Lim R, Plodinec M, Nigg E. Structural centrosome aberrations promote non-cell-autonomous invasiveness. EMBO J. 2018;37: pubmed publisher

Zhu S, Shanbhag V, Wang Y, Lee J, PETRIS M. A Role for The ATP7A Copper Transporter in Tumorigenesis and Cisplatin Resistance. J Cancer. 2017;8:1952-1958 pubmed publisher

Valverde A, Peñarando J, Cañas A, Lopez Sanchez L, Conde F, Guil Luna S, et al. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-?- catenin signaling axis. Oncotarget. 2017;8:21754-21769 pubmed publisher

DeSmet M, Fleet J. Constitutively active RAS signaling reduces 1,25 dihydroxyvitamin D-mediated gene transcription in intestinal epithelial cells by reducing vitamin D receptor expression. J Steroid Biochem Mol Biol. 2017;173:194-201 pubmed publisher

Valverde A, Peñarando J, Cañas A, López Sánchez L, Conde F, Hernández V, et al. Simultaneous inhibition of EGFR/VEGFR and cyclooxygenase-2 targets stemness-related pathways in colorectal cancer cells. PLoS ONE. 2015;10:e0131363 pubmed publisher

Unni A, Lockwood W, Zejnullahu K, Lee Lin S, Varmus H. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma. elife. 2015;4:e06907 pubmed publisher

Garant K, Shmulevitz M, Pan L, Daigle R, Ahn D, Gujar S, et al. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release. Oncogene. 2016;35:771-82 pubmed publisher

Leiser D, Medová M, Mikami K, Nisa L, Stroka D, Blaukat A, et al. KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells. Mol Oncol. 2015;9:1434-46 pubmed publisher

Tong J, Lung R, Sin F, Law P, Kang W, Chan A, et al. Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biol Ther. 2014;15:768-76 pubmed publisher

Hu Y, Zheng M, Gali R, Tian Z, Topal Görgün G, Munshi N, et al. A novel rapid-onset high-penetrance plasmacytoma mouse model driven by deregulation of cMYC cooperating with KRAS12V in BALB/c mice. Blood Cancer J. 2013;3:e156 pubmed publisher

Mao X, Hütt Cabezas M, Orr B, Weingart M, Taylor I, Rajan A, et al. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget. 2013;4:1050-64 pubmed

Khosravi Far R, White M, Westwick J, Solski P, Chrzanowska Wodnicka M, Van Aelst L, et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol. 1996;16:3923-33 pubmed